AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

The crucial drugs can have unintended consequences. Innovative therapies could shield the microbiome from their effects.

An expert briefly describes the study ‘Single Dose Aminoglycosides versus Carbapenems for the Treatment of Uncomplicated ...

Traditional diagnostic methods, such as bacterial culture and PCR-based testing, can take 24–72 hours, delaying critical ...

为解决发展中国家手术部位感染（SSIs）相关数据匮乏问题，埃塞俄比亚 Arba Minch General Hospital 研究人员研究 SSIs 流行、微生物谱及相关因素。发现 SSIs 患病率高且耐药严重，该研究对防控感染、合理用药意义重大，值得科研读者一读。

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Through this platform, resistance in bacterial samples can be tested within two hours compared to 24-27 hours through other ...

Addresses the significant threat of antimicrobial resistance.